Combined Modality Therapy – Talk Bio

Actionable Insights Powered by AI

Gilead Bolsters Trodelvy in Triple-Negative Breast Cancer With Practice-Changing Keytruda Combo Win

4 days ago talkbio0Tagged Antibody-Drug Conjugates, Combined Modality Therapy, Gilead Sciences, Immunotherapy, Keytruda, Phase 3 trial, practice-changing, Progression-Free Survival, TNBC, Triple Negative Breast Neoplasms, Trodelvy

Gilead Sciences; Trodelvy; Keytruda; triple-negative breast cancer; TNBC; antibody-drug conjugate; immunotherapy; progression-free survival; ASCO 2025; phase 3 trial; practice-changing; combination therapy

Boundless Bio Lays Off 33% of Staff Following Stumble of Lead Program

2 weeks ago talkbio0Tagged BBI-355, BBI-825, Bio, Boundless, CHEK1 protein, human, Clinical Trials, Combined Modality Therapy, Inhibitor, layoffs, pipeline restructuring, ribonucleoside-diphosphate reductase activity, Solid Neoplasm

Boundless Bio; layoffs; biotech; clinical trial; BBI-355; BBI-825; RNR inhibitor; CHK1 inhibitor; combination therapy; solid tumors; pipeline restructuring

FDA Approves Pfizer’s Adcetris Combination Therapy for Relapsed/Refractory Large B-cell Lymphoma

4 months ago talkbio0Tagged Adcetris, Antibody-Drug Conjugates, Approved, BRENTUXIMAB, Combined Modality Therapy, Diffuse Large B-Cell Lymphoma, LBCL, Pfizer, United States Food and Drug Administration, vedotin

Adcetris, brentuximab vedotin, FDA approval, large B-cell lymphoma, LBCL, DLBCL, antibody-drug conjugate, Pfizer, combination therapy

Pfizer’s Subcutaneous PD-1 Inhibitor Sasanlimab Achieves Significant Efficacy in High-Risk Non-Muscle Invasive Bladder Cancer

5 months ago talkbio0Tagged BCG Vaccine, BCG-Naïve, Combined Modality Therapy, Event-Free Survival, Inhibitor, Invasive, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, PDCD1 gene, Pfizer, Sasanlimab, subcutaneous

Pfizer, Sasanlimab, Subcutaneous PD-1 inhibitor, Non-muscle invasive bladder cancer (NMIBC), BCG-naïve, Event-free survival (EFS), Combination therapy with BCG

J&J’s Rybrevant Combination Therapy Outperforms AstraZeneca’s Tagrisso in Lung Cancer Survival Trial

5 months ago talkbio0Tagged AstraZeneca, Combined Modality Therapy, J&J, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Rybrevant, survival trial, Tagrisso

J&J, Rybrevant, AstraZeneca, Tagrisso, lung cancer, NSCLC, survival trial, combination therapy

BioNTech Advances PD-L1/VEGF Bispecific Antibody with Encouraging Breast Cancer Trial Results

6 months ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327/PM8002, Clinical Trials, Combined Modality Therapy, Malignant neoplasm of breast, PD-L1/VEGF

BioNTech, PD-L1/VEGF Bispecific Antibody, BNT327/PM8002, Breast Cancer, Oncology Strategy, Clinical Trials, Combination Therapies

Crescent Biopharma’s Public Debut Fueled by PD-1/VEGF Combination Therapy Enthusiasm

7 months ago talkbio0Tagged biopharmaceutical industry, Combined Modality Therapy, inhibitors, Malignant Neoplasms, PD-1/PD-L1, Public Listing, Vascular Endothelial Growth Factor A

PD-1/PD-L1 inhibitors, VEGF inhibitors, Combination therapy, Cancer treatment, Biopharmaceutical industry, Public listing

Sarclisa Gains FDA Approval as First-Line Treatment for Newly Diagnosed Multiple Myeloma

9 months ago talkbio0Tagged Approved, Combined Modality Therapy, first-line, isatuximab, Multiple Myeloma, sanofi, Sarclisa, United States Food and Drug Administration, VRd

Sarclisa, FDA approval, first-line treatment, multiple myeloma, Sanofi, isatuximab, VRd combination therapy.

GSK’s Zejula Fails to Meet Overall Survival Goal in First-Line Ovarian Cancer, Combination Therapy Disappoints

9 months ago talkbio0Tagged Combined Modality Therapy, first-line, Maintenance, niraparib, ovarian neoplasm, Overall Survival, Restricted, second-line, SmithKline Beecham, United States Food and Drug Administration, Zejula

Zejula, niraparib, GSK, ovarian cancer, first-line treatment, overall survival, combination therapy, FDA, restriction, second-line maintenance

Bristol Myers Advances Opdualag into Phase 3 Trials for First-Line Lung Cancer

9 months ago talkbio0Tagged Combined Modality Therapy, first-line, LAG-3/PD-1, Malignant neoplasm of lung, Myers, Opdualag, squibb

Opdualag, Bristol Myers Squibb, lung cancer, first-line treatment, phase 3 trials, LAG-3/PD-1 combination therapy